<DOC>
	<DOC>NCT02932150</DOC>
	<brief_summary>The primary objectives of this study are as follows: Part A: To evaluate the steady state pharmacokinetics (PK) of tenofovir alafenamide (TAF) and confirm the dose of TAF 25 mg tablet given once daily in treatment-naive and treatment-experienced adolescents (aged 12 to &lt; 18 years) with chronic hepatitis B (CHB) Part B: To evaluate the safety, tolerability, and antiviral activity (HBV DNA &lt; 20 IU/mL) of TAF 25 mg once daily versus placebo through Week 24 in treatment-naive and treatment-experienced adolescents with CHB.</brief_summary>
	<brief_title>Tenofovir Alafenamide (TAF) in Adolescents With Chronic Hepatitis B Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Key Inclusion criteria: Males and nonpregnant, nonlactating females Weight at Screening: ≥ 35 kg (77 lbs) Able to swallow oral tablets Willing and able to provide written informed consent/assent (child and parent/legal guardian) Documented evidence of CHB (eg, HBsAgpositive for ≥ 6 months) Treatmentnaive or treatmentexperienced will be eligible for enrollment. Estimated creatinine clearance (CLCr) ≥ 80 mL/min/1.73m^2 (using the Schwartz formula) Normal ECG Key Exclusion criteria: Females who are breastfeeding Males and females of reproductive potential who are unwilling to use an "effective", protocolspecified method(s) of contraception during the study. Coinfection with hepatitis C virus (HCV), HIV, or hepatitis D virus (HDV) Evidence of hepatocellular carcinoma Any history of, or current evidence of, clinical hepatic decompensation Abnormal hematological and biochemical parameters Received solid organ or bone marrow transplant Currently receiving therapy with immunomodulators (eg, corticosteroids), or immunosuppressants Significant renal, cardiovascular, pulmonary, or neurological disease in the opinion of the Investigator Malignancy within the 5 years prior to screening. Individuals under evaluation for possible malignancy are not eligible. Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance. Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CHB</keyword>
	<keyword>HBV</keyword>
</DOC>